What is HOMA-IR and what changes have been observed with GLP-1 agonists?

HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is a validated fasting-state index calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)] / 22.5. Lower values indicate greater insulin sensitivity. Clinical trials consistently show that GLP-1 receptor agonists reduce HOMA-IR by 20–40% from baseline, driven by both the fall in fasting insulin (from reduced beta-cell secretory demand as glucose levels decrease) and the fall in fasting glucose. Tirzepatide produces the largest documented HOMA-IR reductions across the class, with SURPASS trials reporting mean reductions of approximately 35–45% at the 15 mg dose.

How does the GIP receptor contribute to insulin sensitisation?

GIP receptors are expressed abundantly in adipose tissue, and adipose GIP receptor signalling promotes insulin-mediated glucose uptake in adipocytes, stimulates lipoprotein lipase activity, and suppresses lipolysis after meals — all actions that reduce the circulating NEFA load that drives hepatic and skeletal-muscle insulin resistance. Tirzepatide's GIP receptor agonism thus sensitises adipose tissue to insulin independently of GLP-1 receptor effects, creating an adipose-tissue axis of insulin sensitisation that is mechanistically distinct from the GLP-1 axis operating primarily at beta cells, central nervous system, and skeletal muscle.

What is the difference between hepatic and peripheral insulin resistance?

Hepatic insulin resistance refers to the liver's failure to suppress gluconeogenesis and glycogenolysis in response to insulin, producing elevated fasting glucose and increased hepatic glucose output. Peripheral insulin resistance refers to reduced insulin-mediated glucose uptake in skeletal muscle, the largest glucose-consuming tissue. In T2DM, hepatic resistance typically drives fasting hyperglycaemia while peripheral resistance limits postprandial glucose disposal. GLP-1 receptor agonists appear to address both: hepatic resistance via reduced portal NEFA flux (secondary to adipose mobilisation and weight loss) and peripheral resistance via weight loss and potentially direct skeletal muscle GLP-1 receptor effects.

What does the hyperinsulinaemic euglycaemic clamp show for incretin agents?

The gold-standard measure of insulin sensitivity is the hyperinsulinaemic euglycaemic clamp, which quantifies the glucose infusion rate required to maintain euglycaemia under a fixed insulin infusion — the higher the required infusion rate, the more insulin-sensitive the tissues. Clamp studies during GLP-1 agonist treatment show improvements in whole-body glucose disposal rates. A notable limitation is that clamp studies are challenging to conduct at scale, so most large trials rely on HOMA-IR and HbA1c as proxies, with mechanistic clamp data generated in smaller sub-studies.

Does the improvement in insulin resistance with incretin agents persist if treatment is stopped?

Available evidence, primarily from semaglutide discontinuation (STEP-4) and structured withdrawal studies, indicates that insulin sensitivity improvements largely reverse on treatment cessation, paralleling the weight regain trajectory. HOMA-IR returns towards baseline values as body weight and adiposity increase after stopping treatment. This underscores that insulin resistance improvement in the context of incretin pharmacology is primarily state-dependent (maintained by ongoing pharmacological action and reduced adiposity) rather than a durable reset of the underlying insulin resistance biology.

Insulin Resistance: Metabolic Peptide Research (UK 2026)

The condition in 60 seconds

Insulin resistance — the reduced ability of cells to respond normally to insulin signalling — is the central metabolic defect linking obesity, T2DM, NASH, cardiovascular disease, and polycystic ovary syndrome. It is estimated to affect approximately 35% of UK adults in some degree, rising to over 80% in adults with BMI above 35 kg/m². Unlike T2DM or obesity, insulin resistance is not a standalone diagnostic entity in UK clinical practice; it is identified biochemically via surrogate markers (HOMA-IR, fasting insulin) or by physiological measurement (hyperinsulinaemic euglycaemic clamp) in research settings.

The pathophysiology of insulin resistance involves multiple tissue compartments in a self-amplifying cycle: excess adipose tissue — particularly visceral depots — releases high concentrations of non-esterified fatty acids and pro-inflammatory cytokines (TNF-alpha, IL-6, resistin) that impair insulin signal transduction in skeletal muscle and liver via serine phosphorylation of IRS-1, activation of NF-kB, and accumulation of intracellular lipid intermediates (diacylglycerols, ceramides). Pancreatic beta cells initially compensate through hypersecretion of insulin, maintaining glucose homeostasis but elevating cardiovascular risk through hyperinsulinaemia-driven dyslipidaemia and endothelial dysfunction. As beta-cell reserve is exhausted, T2DM develops.

Why metabolic peptides matter here

The incretin class addresses insulin resistance through a multi-tissue mechanism that is more physiologically comprehensive than any earlier pharmacological class. Rather than simply augmenting insulin secretion (sulfonylureas) or reducing hepatic glucose output (metformin), GLP-1 and GIP receptor agonists modify the upstream drivers of insulin resistance: adipose tissue biology, portal NEFA flux, hepatic lipid content, and inflammatory cytokine networks.

GLP-1 receptor activation reduces insulin secretory demand by lowering postprandial glucose excursions, reducing the chronic hyperglycaemia-driven glucotoxicity that impairs IRS-1 signalling in insulin-sensitive tissues. The weight and visceral fat reduction achieved with semaglutide and tirzepatide reduces the NEFA and adipokine-mediated peripheral resistance burden. Tirzepatide's GIP receptor agonism provides an additional mechanism specifically at adipose tissue, where GIP receptor activation promotes insulin-mediated glucose uptake, suppresses lipolysis, and potentially reduces the pro-inflammatory adipocyte phenotype that sustains systemic resistance.

There is also emerging evidence for direct GLP-1 receptor effects on skeletal muscle — the major site of peripheral insulin-mediated glucose disposal. GLP-1 receptors are expressed in skeletal muscle, and mechanistic studies in humans suggest GLP-1 receptor agonism may augment muscle glucose uptake independently of weight change, though the magnitude of this direct effect is likely modest relative to the weight-mediated improvement.

The trial landscape

SURPASS programme HOMA-IR analyses: All five SURPASS trials reported HOMA-IR as a secondary endpoint. SURPASS-2, the largest head-to-head comparison of tirzepatide and semaglutide, showed tirzepatide at all doses produced greater HOMA-IR reductions than semaglutide 1 mg — with tirzepatide 15 mg achieving approximately 44% HOMA-IR reduction versus approximately 29% with semaglutide 1 mg. This difference exceeds what would be expected from the differential weight loss alone, suggesting a GIP-receptor-specific insulin sensitisation contribution.

SURMOUNT HOMA-IR and insulin sub-studies: In SURMOUNT-1, HOMA-IR and fasting insulin were pre-specified secondary endpoints. At 72 weeks, tirzepatide 15 mg reduced fasting insulin by approximately 50% and HOMA-IR by approximately 48% from baseline, consistent with a profound improvement in insulin sensitivity accompanying the 20%+ weight reduction. Beta-cell function indices (including HOMA-B and the insulinogenic index) improved in parallel, reflecting the reduction in glucotoxic stress on pancreatic islets.

Hyperinsulinaemic euglycaemic clamp sub-studies: Mechanistic clamp studies have been conducted in smaller research populations receiving semaglutide and tirzepatide. A sub-study within the SURPASS programme used the two-step clamp (low and high insulin infusion rates, providing separate hepatic and peripheral sensitivity estimates). Tirzepatide produced improvements in both hepatic (suppression of endogenous glucose production) and peripheral (glucose disposal rate) sensitivity, with the peripheral improvement particularly pronounced at higher doses — consistent with GIP receptor effects on adipose and muscle.

GIP receptor knockout data (mechanistic): The adipose GIP receptor axis was clarified by animal studies using GIP receptor knockout models, which showed that GIP receptor loss produced adipose tissue insulin resistance even under normal feeding conditions. This preclinical evidence underpins the clinical hypothesis that tirzepatide's GIP component specifically restores adipose insulin sensitivity — an effect that would be absent with GLP-1 monoagonists.

Liraglutide and insulin resistance (LEAD programme): LEAD-3 and LEAD-5 sub-analyses reported HOMA-IR improvements of approximately 15–25% with liraglutide 1.8 mg, smaller in absolute terms than those observed with semaglutide and tirzepatide, reflecting the dose-dependent and generation-specific pattern of insulin sensitivity improvement across the incretin class.

Pivotal findings

SURPASS-2 HOMA-IR (tirzepatide 15 mg): −44% from baseline versus −29% with semaglutide 1 mg — a statistically significant between-group difference that exceeds what weight differential alone would predict, supporting a GIP-receptor-specific insulin sensitisation mechanism.
SURMOUNT-1 fasting insulin (tirzepatide 15 mg): Approximately 50% reduction in fasting insulin over 72 weeks — the largest pharmacologically induced fasting insulin reduction documented in a phase 3 randomised controlled trial at equivalent timescales.
Clamp glucose disposal rate (tirzepatide): Mechanistic studies reported improvements in whole-body glucose disposal rate of approximately 30–40% from baseline, indicating meaningful peripheral insulin sensitisation at the tissue level beyond what HOMA-IR can fully characterise.
Hepatic insulin resistance reversal: Endogenous glucose production (a clamp-derived measure of hepatic insulin resistance) was significantly suppressed with tirzepatide and semaglutide versus placebo, consistent with reduced hepatic fat content (demonstrated by MRI-PDFF sub-studies) as the mechanistic driver of hepatic insulin sensitisation.
GIP receptor adipose axis: Adiponectin — the insulin-sensitising adipokine reduced in visceral obesity — increased with tirzepatide treatment in SURPASS sub-studies, consistent with restoration of adipose GIP receptor signalling improving adipocyte metabolic function.

UK clinical and research positioning

Insulin resistance measurement is not a routine NHS clinical test; HOMA-IR calculation requires fasting insulin measurement, which is not included in the standard T2DM monitoring pathway. However, it is extensively used in UK academic research centres, clinical trials, and mechanistic studies. UK research groups at the Universities of Newcastle, Manchester, and Imperial College London have used hyperinsulinaemic clamp methodology alongside GLP-1 agonist treatment to characterise the tissue-specific insulin sensitisation mechanisms in human subjects, generating foundational mechanistic data that complement the larger outcome trials.

The UK Biobank and the UKPDS (United Kingdom Prospective Diabetes Study) cohorts provide rich longitudinal datasets for investigating insulin resistance trajectories and the relationship between insulin sensitivity markers and outcomes. Researchers integrating pharmacological intervention data from SURPASS and SURMOUNT with UKPDS-derived epidemiological models are active in quantifying the potential population-level impact of widespread incretin prescribing on T2DM incidence and progression.

NICE guidance on T2DM management (NG28, with ongoing updates) acknowledges insulin sensitisation as a therapeutic goal but does not prescribe specific HOMA-IR targets for clinical management. For UK clinicians, the relevant proxies remain HbA1c and weight, with HOMA-IR reserved for research contexts. The mechanistic evidence base for GIP-axis insulin sensitisation is of particular interest to UK diabetologists as it provides a scientific rationale for the superiority of tirzepatide over GLP-1 monoagonists that is distinct from simple dose-equivalence comparisons.

Methodological caveats

HOMA-IR has well-documented limitations: it captures only the fasting steady state, does not reflect dynamic insulin secretion or postprandial glucose dynamics, and is influenced by the insulin assay used — creating inter-laboratory variability that complicates cross-trial comparisons. Clamp studies provide superior mechanistic resolution but are conducted in small mechanistic sub-studies (typically 30–80 participants) that are insufficiently powered to detect small between-agent differences. Most HOMA-IR data from incretin trials is confounded by concurrent weight loss, making it methodologically difficult to isolate a direct weight- independent insulin sensitisation effect without controlled weight-clamped designs. Adipose tissue biopsy data for GIP receptor expression and signalling in human subjects, while accumulating, are still derived from small mechanistic studies with variable protocols.

Frequently asked questions

What is HOMA-IR and what changes have been observed with GLP-1 agonists?: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is a validated fasting-state index calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)] / 22.5. Lower values indicate greater insulin sensitivity. Clinical trials consistently show that GLP-1 receptor agonists reduce HOMA-IR by 20–40% from baseline, driven by both the fall in fasting insulin (from reduced beta-cell secretory demand as glucose levels decrease) and the fall in fasting glucose. Tirzepatide produces the largest documented HOMA-IR reductions across the class, with SURPASS trials reporting mean reductions of approximately 35–45% at the 15 mg dose.
How does the GIP receptor contribute to insulin sensitisation?: GIP receptors are expressed abundantly in adipose tissue, and adipose GIP receptor signalling promotes insulin-mediated glucose uptake in adipocytes, stimulates lipoprotein lipase activity, and suppresses lipolysis after meals — all actions that reduce the circulating NEFA load that drives hepatic and skeletal-muscle insulin resistance. Tirzepatide's GIP receptor agonism thus sensitises adipose tissue to insulin independently of GLP-1 receptor effects, creating an adipose-tissue axis of insulin sensitisation that is mechanistically distinct from the GLP-1 axis operating primarily at beta cells, central nervous system, and skeletal muscle.
What is the difference between hepatic and peripheral insulin resistance?: Hepatic insulin resistance refers to the liver's failure to suppress gluconeogenesis and glycogenolysis in response to insulin, producing elevated fasting glucose and increased hepatic glucose output. Peripheral insulin resistance refers to reduced insulin-mediated glucose uptake in skeletal muscle, the largest glucose-consuming tissue. In T2DM, hepatic resistance typically drives fasting hyperglycaemia while peripheral resistance limits postprandial glucose disposal. GLP-1 receptor agonists appear to address both: hepatic resistance via reduced portal NEFA flux (secondary to adipose mobilisation and weight loss) and peripheral resistance via weight loss and potentially direct skeletal muscle GLP-1 receptor effects.
What does the hyperinsulinaemic euglycaemic clamp show for incretin agents?: The gold-standard measure of insulin sensitivity is the hyperinsulinaemic euglycaemic clamp, which quantifies the glucose infusion rate required to maintain euglycaemia under a fixed insulin infusion — the higher the required infusion rate, the more insulin-sensitive the tissues. Clamp studies during GLP-1 agonist treatment show improvements in whole-body glucose disposal rates. A notable limitation is that clamp studies are challenging to conduct at scale, so most large trials rely on HOMA-IR and HbA1c as proxies, with mechanistic clamp data generated in smaller sub-studies.
Does the improvement in insulin resistance with incretin agents persist if treatment is stopped?: Available evidence, primarily from semaglutide discontinuation (STEP-4) and structured withdrawal studies, indicates that insulin sensitivity improvements largely reverse on treatment cessation, paralleling the weight regain trajectory. HOMA-IR returns towards baseline values as body weight and adiposity increase after stopping treatment. This underscores that insulin resistance improvement in the context of incretin pharmacology is primarily state-dependent (maintained by ongoing pharmacological action and reduced adiposity) rather than a durable reset of the underlying insulin resistance biology.

Related peptide profiles: Tirzepatide · Semaglutide · Liraglutide. Brand references: Mounjaro · Ozempic. Compare: Semaglutide vs Tirzepatide. Also see: Type 2 diabetes research evidence · Visceral adiposity research.